Table 2.

Retention and opioid use outcomes by medication condition and presence of non-prescribed opioids at baseline, N=120

Variable	Galantamine			Placebo			TOTAL			Medication			Pretreatment opioid use			Medication by pretreatment opioid use status
	Mean	SD	n	Mean	SD	n	Mean	SD	n	F	p	Eta2p	F	p	Eta2p	F	p	Eta2p
Within-treatment outcomes
Retention-Days in treatment (of 84 possible)
No pretreatment opioid use	61.75	34.13	24	73.00	24.06	25	67.49	29.66	49	2.58	.11	.02	.98	.32	.01	.43	.51	.00
Pretreatment opioid use	69.94	27.04	31	74.68	22.68	40	72.61	24.61	71
% opioid-negative urine specimens
No pretreatment opioid use	94.64	12.57	23	87.34	17.57	24	90.91	15.61	47	4.32	.04	.04	41.91	.00	.27	.59	.45	.01
Pretreatment opioid use	62.90	32.99	30	47.07	37.70	39	53.95	36.34	69
% days of opioid abstinence-self report
No pretreatment opioid use	98.91	3.68	24	95.38	12.45	25	97.11	9.34	49	3.29	.07	.03	22.36	.00	.16	.30	.58	.00
Pretreatment opioid use	87.23	14.59	29	80.63	19.77	40	83.40	17.96	69
% cocaine-negative urine samples
No pretreatment opioid use	18.94	31.26	23	22.67	27.69	24	20.84	29.23	47	1.48	.23	.01	.33	.57	.00	3.55	.06	.03
Pretreatment opioid use	32.66	36.76	30	15.34	22.14	39	22.88	30.41	69
Six-month follow-up outcomes
Percent opioid-negative urine specimens
No pretreatment opioid use	95.14	13.44	24	74.00	32.66	25	84.35	27.09	49	10.2	.00	.08	16.94	.00	.13	.07	.80	.00
Pretreatment opioid use	68.39	35.73	29	50.42	37.65	40	57.97	37.66	69